The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Aclaris Therapeutics (ACRS) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Aclaris Therapeutics is one of 916 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aclaris Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ACRS' full-year earnings has moved 3.8% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ACRS has returned about 25.3% since the start of the calendar year. In comparison, Medical companies have returned an average of 5.4%. This shows that Aclaris Therapeutics is outperforming its peers so far this year.
Another stock in the Medical sector, Glaukos (GKOS), has outperformed the sector so far this year. The stock's year-to-date return is 53.6%.
The consensus estimate for Glaukos' current year EPS has increased 44.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Aclaris Therapeutics belongs to the Medical - Drugs industry, which includes 133 individual stocks and currently sits at #96 in the Zacks Industry Rank. On average, this group has lost an average of 2.5% so far this year, meaning that ACRS is performing better in terms of year-to-date returns.
Glaukos, however, belongs to the Medical - Instruments industry. Currently, this 78-stock industry is ranked #99. The industry has moved -2.1% so far this year.
Investors with an interest in Medical stocks should continue to track Aclaris Therapeutics and Glaukos. These stocks will be looking to continue their solid performance.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aclaris Therapeutics, Inc. (ACRS): Free Stock Analysis Report
Glaukos Corporation (GKOS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).